Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU/L

• DOI: 10.1007/s13277-016-5228-2
• Publication Date: 2016-08-10T06:42:16Z
• Authors: Rujiao Liu; Jun Cao; Xiang Gao; Jian Zhang; Leiping Wang; Biyun Wang; Lin Guo; Xichun Hu; Zhonghua Wang
• Keywords: Single Center

High level of serum lactate dehydrogenase (LDH) is a well-known poor prognostic factor in patients with malignancies. However, there was no data on overall survival (OS) cancer LDH > 1000 IU/L, and the value changes over time for OS had not been reported. Clinical 311 metastatic disease >1000 IU/L (four times upper limit normal) admitted consecutively to single center were reviewed this retrospective study. ranged from 1002 8235 U/L mean 1689 U/L. The median 1.7 months (95 % CI: 1.4-2.0). About half (n = 163, 52 %) died within 2 0.5 0.3-0.7). Only 173 indicated salvage treatment. Fifty-one patients' decreased normal at following chemotherapy; significantly longer these (22.6 months, 95 10.9-34.3, p < 0.001) compared those persistently abnormal (4.0 3.4-4.6). independent factors that increased death risk ECOG performance status 3-4 (HR: 2.05, 1.42-2.97, 0.001), supportive care only 2.91, 2.06-4.10, 2.72, 1.67-4.42, 0.001). In conclusion, predicted terminal stage patients. prolonged effective palliative treatment months.